Healthcare VCs Deploy Capital Across Clinical-Stage Therapeutics as AI Infrastructure Absorbs Late-Stage Mega-Rounds
Venture capital is bifurcating between massive late-stage AI infrastructure rounds like Anthropic's $30B at a $380B valuation and robust early-stage healthcare funding. Specialized investors including Roseland Advisors, Brandon Capital, and ADAR1 Capital Management are backing clinical-stage companies like R1 Therapeutics, Equillium, and Biofrontera while Series A/B activity accelerates across therapeutics and medical technology in March 2026.
Salvado•